

| | | | | | |
|--|--------------------|----|--------------------------|------------------|--|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/698,099 | |
| | | | Filing Date | October 31, 2003 | |
| | | | First Named Inventor | Schenk, Dale B. | |
| | | | Art Unit | 1648 | |
| Examiner Name | Michelle S. Homing | | | | |
| Attorney Docket Number | 015270-008930US | | | | |
| Sheet | 1 | of | 4 | | |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 239 | US 5,807,741 | 09-15-1998 | Brown et al. | |
| | 219 | US-5,753,624 | 05-19-1998 | McMichael | |

| U.S. PATENT APPLICATIONS | | | | | |
|--------------------------|-----------------------|--|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 214 | US-11/894,772 | 08-20-2007 | Schenk et al. | |
| | 215 | US-11/894,744 | 08-20-2007 | Schenk et al. | |
| | 216 | US-11/894,605 | 08-20-2007 | Schenk et al. | |
| | 217 | US-11/842,054 | 08-20-2007 | Schenk et al. | |
| | 218 | US-11/841,996 | 08-20-2007 | Schenk et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|---|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | 227 | WO | 01/60794 | A2 | 08-23-2001 | University of California | | <input type="checkbox"/> |
| | 228 | WO | 01/60794 | A3 | 08-23-2001 | University of California | | <input type="checkbox"/> |
| | 220 | WO | 03/045128 | A2 | 06-05-2003 | New York University | | <input type="checkbox"/> |
| | 221 | WO | 03/045128 | A3 | 06-05-2003 | New York University | | <input type="checkbox"/> |
| | 235 | WO | 03/000714 | A2 | 01-03-2003 | New York University | | <input type="checkbox"/> |
| | 236 | WO | 03/000714 | A3 | 01-03-2003 | New York University | | <input type="checkbox"/> |
| | 222 | WO | 08/103472 | A2 | 08-28-2008 | Elan Pharmaceuticals, Inc. et al. | | <input type="checkbox"/> |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

| | | | |
|--|---|--------------------------|---------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 10/698,099 |
| | | Filing Date | October 31, 2003 |
| | | First Named Inventor | Schenk, Dale B. |
| | | Art Unit | 1648 |
| | | Examiner Name | Michelle S. Horning |
| (Use as many sheets as necessary) | | Attorney Docket Number | 015270-008930US |
| Sheet | 2 | of | 4 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 226 | ANDERSON et al., "Phosphorylation of SER-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease," <i>The Journal of Biological Chemistry</i> , 281:29739-29752 (2006). | <input type="checkbox"/> |
| | 240 | Alves da Costa, "Recent Advances on α -Synuclein Cell Biology : Functions and Dysfunctions," <i>Current Molecular Medicines</i> , 3:17-24 (2003). | <input type="checkbox"/> |
| | 241 | CASADESUS et al., "The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease," <i>Drugs R&D</i> , 7(3):187-193 (2006). | <input type="checkbox"/> |
| | 224 | CHILCOTE et al., "Comparison of alpha-synuclein species in Lewy bodies and the soluble fraction of diffuse Lewy body disease brain," Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003) Abstract only. | <input type="checkbox"/> |
| | 83 | CLELAND et al., "Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21," <i>J. of Pharm Sci.</i> , 85(1): 22-28 (1996). | <input type="checkbox"/> |
| | 87 | DEMATOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," published online before print July 3, 2001 at 10.1073/pnas.151261398; <i>PNAS</i> , 98(15):8850-8855 (2001). | <input type="checkbox"/> |
| | 237 | EP 03783083.3 European Supplementary Search Report completed 10/10/2008. | <input type="checkbox"/> |
| | 238 | EP 05814041.9 European Supplementary Search Report completed 10/29/2008. | <input type="checkbox"/> |
| | 104 | FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994). | <input type="checkbox"/> |
| | 242 | JANEWAY et al., <i>Immunology</i> , 3 rd edition, 8:18-8:19 (1997). | <input type="checkbox"/> |
| | 229 | HASHIMOTO et al., "A-synuclein inhibits [alpha]-synuclein aggregation: A possible role as an anti-Parkinsonian factor", <i>NEURON</i> , 32(2):213-223 (2001). | <input type="checkbox"/> |

| | |
|-----------------------|--------------------|
| Examiner Signature | Date Considered |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/698,099 |
| | | | | Filing Date | October 31, 2003 |
| | | | | First Named Inventor | Schenk, Dale B. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Michelle S. Horning |
| Sheet | 3 | of | 4 | Attorney Docket Number | 015270-008930US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | T ² |
| | 233 | HEISER et al., "Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy," Proceedings of the National Academy of Sciences of USA, 97(12):6739-6744 (2000), Abstract only. | | <input type="checkbox"/> |
| | 232 | LECERF et al., "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease," Proceeding of the National Academy of Sciences of USA, 98(8):4764-4769 (2001). | | <input type="checkbox"/> |
| | 126 | LEE et al., "Human α -synuclein-harboring familial Parkinson's disease-linked Ala-53 \rightarrow Thr mutation causes neurodegenerative disease with α -synuclein aggregation in transgenic mice," PNAS, 99:8968-8973 (2002). | | <input type="checkbox"/> |
| | 225 | LEE et al., "Truncated alpha-synuclein is generated in vivo and potentiates alpha synuclein aggregation," Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003), Abstract only. | | <input type="checkbox"/> |
| | 243 | PERRIN et al., "Epitope mapping and specificity of the anti- α -synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines," <u>Neuroscience Letters</u> , 349:1331-1335 (2003), abstract only. | | <input type="checkbox"/> |
| | 234 | ROCHET et al., "Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α -synuclein" <u>Biochemistry</u> , 39(35):10619-10628 (2000), abstract only. | | <input type="checkbox"/> |
| | 244 | SIDU et al., "Does α -synuclein modulate dopaminergic synaptic content and tone at the synapse," FASEB, 18:637-647 (2004). | | <input type="checkbox"/> |
| | 245 | SPILLANTINI et al., " α -Synuclein in Lewy bodies," <u>Nature</u> , 388:839-840 (1997). | | <input type="checkbox"/> |
| | 246 | TAKEDA et al., "Abnormal Accumulation of NACP/ α -Synuclein in Neurodegenerative Disorders," <u>American Journal of Pathology</u> , 152:367-372 (1998). | | <input type="checkbox"/> |
| | 247 | TOFARIS et al., "Physiological and Pathological Properties of α -synuclein," <u>Cellular and Molecular Life Sciences</u> , pp. 1-8 (2007). | | <input type="checkbox"/> |
| | 223 | TOFARIS et al., "Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function," <u>The Journal of Biological Chemistry</u> , 278: 44405-44411 (2003). | | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|---|----|---|--------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/698,099 |
| | | | | Filing Date | October 31, 2003 |
| | | | | First Named Inventor | Schenk, Dale B. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Michelle S. Horning |
| Sheet | 4 | of | 4 | Attorney Docket Number | 015270-008930US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 231 | WANKER, "Protein aggregation in Huntington's and Parkinson's disease: Implications or therapy," Molecular Medicine Today 2000 GB, 6(10):387-397 (2000), Abstract only. | <input type="checkbox"/> | |
| | 230 | WINDISCH et al., "Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory [beta]-synuclein-derived peptides," Journal of Molecular Neuroscience, 19(2): 63-69 (2002) abstract only. | <input type="checkbox"/> | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Michelle Horning/ | Date Considered | 05/28/2009 |
|-----------------------|--------------------|--------------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.